![KalVista Pharmaceuticals, Inc. logo](/logos/KALV.webp)
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
Overview | Financials
Company Name | KalVista Pharmaceuticals, Inc. |
Symbol | KALV |
Currency | USD |
Price | 12.34 |
Market Cap | 531,630,646 |
Dividend Yield | 0% |
52-week-range | 7.21 - 16.88 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Thomas Andrew Crockett M.B.A. |
Website | https://www.kalvista.com |
An error occurred while fetching data.
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD